Keynote speakers

Keynote speakers

The MelNet Executive Committee are pleased to announce the following keynote speakers for the 2018 New Zealand Melanoma Summit.

Check out the draft programme here.


Associate Professor Cliff Rosendahl MBBS PhD

Director of the Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia  Distinguished Visiting Professor at Tehran University of Medical Sciences, Iran

ADDRESS: Artificial intelligence and advances in dermatoscopy and teledermatoscopy

Associate Professor Rosendahl is a medical practitioner with over 40 years’ experience. He has a background in general practice and forensic medicine, and has worked in a Brisbane suburban practice as a general practitioner with a special interest in skin cancer, particularly melanoma.  Associate Professor Rosendahl has collaborated with colleagues in Brisbane and Austria to research the early diagnosis of melanoma, and together they have evaluated and promoted the diagnostic methods ‘Chaos and Clues and Prediction without Pigment’. He is founder and a coordinator of the Skin Cancer Audit and Research Database (SCARD). He has published over 50 papers in peer-review scientific journals, is co-author of the textbook Dermatoscopy which is published in eight languages, and is a contributing author to several other textbooks in English and two in Spanish.

Professor John Kelly AM, MD, FACD  

Director, Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia

ADDRESS: Nodular melanoma (an important issue for NZ)

Professor John Kelly founded one of Australia’s largest multidisciplinary treatment services for melanoma, the Victorian Melanoma Service, at the Alfred hospital in 1994. He trained as a dermatologist in Melbourne and undertook his Doctorate at the Melanoma Clinic, University of California, San Francisco, on the subject of melanoma diagnosis and management. With a longstanding interest in melanoma research, Professor Kelly has published more than 100 papers, particularly with respect to clinical features, diagnosis and treatment. Professor Kelly has served on the board of the Australia and New Zealand Melanoma Trials Group, and is a member of the Executive Steering Committee and contributing author for the wiki-based Australian Clinical Practice Guidelines for the Diagnosis and Management of Melanoma 2017.

Professor John Thompson AO, MD, FRACS, FACS

Professor of Melanoma and Surgical Oncology, The University of Sydney; Senior Surgeon, MIA  

Professor Thompson is internationally recognised for his leadership in developing the sentinel node biopsy technique in the management of melanoma. He pioneered the Isolated Limb Perfusion and has trained surgeons around the world in the technique which is now performed regularly. Professor Thompson was the Director of Sydney Melanoma Unit from 1998 and thereafter Executive Director of Melanoma Institute Australia until the end of 2016.  He is a past President of the International Sentinel Node Society, and was Chairman of the Australian and New Zealand Melanoma Trials Group for 15 years. He is a member of the Melanoma Staging Committee of the American Joint Committee on Cancer, and chair of the Working Group responsible for updating the Clinical Practice Guidelines for the Management of Cutaneous Melanoma in Australia and New Zealand.  He is an Honorary Fellow of the American Surgical Association and the American College of Surgeons, and an Inaugural Fellow of the Australian Academy of Health and Medical Sciences. Professor Thompson is author of over 700 peer-reviewed scientific articles and holds positions on the editorial boards of several international journals. Professor Thompson has received several awards for his contribution to cancer research and medical education.

Dr Donna Milne BNurs, Dip CanNurs/Pall, MNurs, PhD  

Advanced Practice Nurse in the Skin and Melanoma Service and a clinical nurse researcher in the Department of Cancer Experiences Research at Peter MacCallum Cancer Centre Victoria, Australia  

Dr Milne is a registered nurse who has been working in cancer care for 22 years. Her PhD investigated the perceptions of palliative care services held by people with advanced cancer. Her current research activities focus on identifying the needs of patients with melanoma and their family members, and the experiences and expectations of patients being treated with immunotherapies. Dr Milne is on the Executive of the Australian and New Zealand Melanoma Trials Group, and is an active member of the Cancer Nurses Society of Australia, Psycho-Oncology Co-operative Research Group and the International Society of Nurses in Cancer Care. Dr Milne sits on national and international nursing advisory boards that advise on the educational and support requirements of patients with melanoma. She has published numerous papers in peer-reviewed journals.

Professor Rod Dunbar MBChB, PhD 

Director Maurice Wilkins Centre, Professor at School of Biological Sciences, University of Auckland

Dr Mary Jane Sneyd BSc MB CHB PhD 

Senior Research Fellow, Hugh Adam Cancer Epidemiology Unit, Dunedin School of Medicine, University of Otago

ADDRESS: Trends in melanoma incidence and mortality in New Zealand and risk assessment in New Zealand

Dr Sneyd is a cancer epidemiologist whose main research interests include descriptive, analytical, and survival studies of melanoma, myeloma, and colorectal, breast and prostate cancers. As well as many descriptive epidemiological projects she has carried out several national case-control studies of cancer in New Zealand and has developed New Zealand–specific risk predictor models for melanoma and breast cancer for use in primary care.

Professor Mike Eccles BSc(Hons), PhD 

New Zealand Institute for Cancer Research Trust Chair in Cancer Pathology, Pathology Department, University of Otago

Dr Rosalie Stephens MD

Medical oncologist, Auckland DHB Oncology services

Dr Richard Martin MBChB, FRACS, ChM 

Surgical Oncologist, New Zealand Melanoma Unit team, Waitemata District Health Board, Auckland Regional Head and Neck Service, Senior Lecturer at the University of Auckland 

ADDRESS: Melanoma Standards update

Professor Peter Shepherd PhD 

Deputy Director Maurice Wilkins Centre